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Background and aims: Although most cases of hereditary haemochromatosis are associated with
homozygosity for the C282Y mutation of the HFE gene, clinical penetrance varies and other genes may
modify disease expression. If so, relatives from clinically affected families, by inheriting such genes, may
accumulate more iron. To seek evidence for this, we compared iron status and morbidity in unselected first
degree relatives of two groups of index cases from South Wales, namely asymptomatic C282Y
homozygotes identified by genetic screening of blood donors (n = 56) and C282Y homozygous
haemochromatosis patients presenting clinically (n = 60).
Methods: All participating relatives had a structured interview, clinical assessment, and laboratory
investigations. Health related quality of life was measured (SF-36 version 2).
Results: In total, 92% of 180 eligible first degree relatives were interviewed in the ‘‘screened’’ family group and
85% of 143 eligible relatives in the ‘‘patient’’ group. Of 59 relatives homozygous for C282Y, 76% of men and
32% of women had the ‘‘iron phenotype’’ (raised transferrin saturation and serum ferritin). Logistic regression
modelling of the iron phenotype risk showed that 42% of the initial model deviance could be explained by
homozygosity for C282Y, another 6% by lifestyle factors, and 6% by being male. Family group membership
was not a significant risk factor. Morbidity and SF-36 scores did not differ significantly either between C282Y
homozygotes and relatives lacking C282Y, or between C282Y homozygotes from the ‘‘screened’’ and
‘‘patient’’ groups. Serious morbidity (including cirrhosis) was low in both groups of relatives.
Conclusions: HFE C282Y homozygosity has a high penetrance for iron accumulation but a low clinical
penetrance. Lack of excess morbidity among C282Y homozygous relatives of index cases who presented
clinically suggests that residual unknown genetic or environmental factors do not greatly influence clinical
outcome among C282Y homozygotes.
H
ereditary haemochromatosis (HH) is an autosomal
recessive condition in which too much iron is absorbed
from the diet. Undetected progressive iron accumula-
tion may have serious clinical consequences, including
arthritis, diabetes, heart disease, and cirrhosis. Premature
illness and death from the disease can be avoided by
phlebotomy, provided treatment begins before cirrhosis has
developed.1 In the UK, over 90% of HH patients are
homozygous for the Cys282Tyr (C282Y) mutation of the
HFE gene on chromosome 6p.2 3 Another 4% are compound
heterozygotes, with C282Y on one chromosome and a second
HFE mutation (mostly His63Asp, H63D) on the other. Rarer
causes of HH include mutations within the HAMP,4 5 TFR2,6
SLC11A3,7–9 and HJV10 genes.
The availability of effective treatment, high frequency of
the C282Y mutation among individuals of northern European
descent,11 and the introduction of a diagnostic test for HFE
gene mutations has led some to advocate HH population
screening.12 13 However, recent research based population
screening has revealed that the clinical penetrance of
homozygous HFE gene mutations is lower than previously
thought.14–16 There is therefore uncertainty and controversy
about the overall clinical significance of HFE C282Y homo-
zygosity17–20 and the overall cost effectiveness of genetic
screening for HH.
In contrast with C282Y homozygotes identified by popula-
tion screening, the prevalence of additional disease predis-
posing factors may be higher in first degree relatives of C282Y
homozygotes who have presented with clinical symptoms
and signs of haemochromatosis. Studies of twins21 and of
several strains of HFE knockout mice indeed suggest that
genetic factors other than HFE play a role in HH aetiology.22 23
Most C282Y homozygous relatives of HH patients have
biochemical evidence of iron accumulation (that is, raised
levels of transferrin saturation), and about 50% of men and a
lower proportion of women were reported to manifest at least
one clinical feature of the disease.24 25 Relatives in these
families who lacked HFE mutations were not investigated,
which limits the conclusions that can be drawn. As well as
endogenous genetic factors, some exogenous exposures also
contribute to the development of serious disease in some
patients. These include alcohol26 and chronic hepatitis C
infection.27
The aim of the present study was to define further the
relative contributions of the HFE gene, genetic influences
other than HFE, and some exogenous factors on the iron
storage phenotype. To test the possibility that the ancestral
haplotype for HFE is associated with more severe iron
overload,28–30 microsatellite markers around the HFE gene
were analysed in family members. To minimise the possibility
Abbreviations: AST, aspartate aminotransferase; Hb, haemoglobin;
HH, hereditary haemochromatosis; MCH, mean cell haemoglobin;
MCV, mean corpuscular volume; PCP, physical component score; QOL,
quality of life; sFe, serum iron concentration; sFn, serum ferritin
concentration; TIBC, total iron binding capacity; UIBC, unsaturated iron
binding capacity; TS, transferrin saturation
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of ascertainment bias, we studied first degree relatives of two
groups of index cases, namely C282Y homozygotes ascer-
tained through a genetic screening programme among
healthy blood donors,31 and C282Y homozygous patients
who presented with clinical HH. We hypothesised that, if
genes other than HFE were of significance in determining the
phenotype, then iron overload (that is, high transferrin
saturation and serum ferritin) would be displayed by a higher
proportion of relatives of clinically affected index cases than
of cases detected by genetic screening.
METHODS
Ascertainment of index cases
Identification of 72 C282Y homozygotes among 10 556 blood
donors has been described elsewhere.31 32 To define the
incidence of HH in South Wales, a rigorous search for cases
was undertaken in the Bro Taf and Gwent Health Authorities,
which serve a population of 1.3 million.16 Extension of the
study to Iechyd Morgannwg Health Authority allowed
identification of a total of 69 HH patients who were
homozygous for HFE C282Y, and who had been treated by
venesection. The study ran from January 1998 to December
1999. Patients selected as index cases for the current study
were those who had presented clinically (rather than by
family or population screening) and were confirmed to be
C282Y homozygous. All were under 70 years of age, the same
age range for the C282Y homozygotes detected by blood
donor screening.
Contacting first degree relatives
All prospective index cases were informed by mail about the
current project and asked to consider discussing the study
with their first degree relatives (parents and siblings over the
age of 18 years), even if they had already been tested for
haemochromatosis. Once written consent to contact a family
member had been obtained, a letter was sent to the relative in
question, outlining the study and inviting their participation.
Those agreeing to participate were then interviewed person-
ally by one of us (AMcC) between July 2001 and December
2002, after written consent was obtained.
Questionnaire
All participants answered a structured interview to record
their demographic details, family history (including details of
deceased first degree relatives), ancestry, medical history, and
current health status. Enquiry was made into all factors
known to affect body iron stores, including details of past and
current blood donation or bleeding disorder, iron/vitamin C
supplementation, and non-steroidal anti-inflammatory drug
use. Additional information was sought from females about
menstrual history, contraceptive pill use, number of preg-
nancies, breast feeding, and fertility. Detailed enquiry was
made into diet, current and past alcohol consumption, tea
and coffee intake, together with full details of their
medication use (both prescribed and over the counter).
All participating relatives were invited to complete a
validated quality of life (QOL) questionnaire. The SF-36
(version 2) health survey, which has been used extensively to
compare health status of different groups,33 was selected
because it provides a generic measure of health status and
yields quantitative scores, as well as summary scores of
physical and mental well being.
The interview usually took place in the individual’s home
and, in most cases, neither physician nor participant were
aware of any genotyping or iron test results. Among 286 first
degree relatives, only 13 had been previously diagnosed as
having HH. Test results recorded for these cases were those
taken at presentation (that is, before venesection). They were
encouraged to respond to questions as best they could recall
from the periods before or after diagnosis, as appropriate.
Clinical notes for these cases were also scrutinised for
inaccuracies arising from recall bias. Any discrepancies were
further clarified with the respondent.
Laboratory analysis
Serum iron (sFe) and unsaturated iron binding capacity
(UIBC) were determined by a microtitre plate assay.34 Total
iron binding capacity (TIBC) and transferrin saturation (TS)
were calculated from sFe and UIBC values.34 Serum ferritin
(sFn) levels were measured on an Elecsys 2010 immunoa-
nalyser (Roche, Lewes, UK). Full blood count and
reticulocyte count (Advia 2120, Maidenhead, UK) and liver
function tests (Aeroset analyser; Abbott Diagnostics) were
also arranged.
DNA was extracted from whole blood. HFE alleles (wild-
type, C282Y, and H63D) were identified by heteroduplex
analysis performed using a capillary electrophoresis system
(GeneScan 310; Applied Biosystems, Warrington, UK).35 36
The ‘‘ancestral’’ haplotype was identified by microsatellite
markers around the HFE gene.37 One polymerase chain
reaction primer of each reaction was labelled with a
fluorescent dye in a multiplex reaction and DNA fragment
sizes were measured on the Applied Biosystems GeneScan
310.
Medical follow up of relatives
First degree relatives found to be C282Y homozygous, but
with normal iron indices, were given their results, offered
counselling, and provided with a written summary of the
findings. Arrangements were made for annual follow up
review. Those with iron abnormalities were sent an explana-
tory letter. Arrangements were made for a follow up
appointment so that the findings could be discussed and
also for any additional clinical assessments that were
required. In accordance with UK Guidelines,38 no separate
provision was made to arrange liver biopsy for C282Y
homozygotes provided they had normal liver function tests,
no hepatomegaly, and sFn ,1000 mg/l, as the risk of
significant fibrosis/cirrhosis is low. Therapeutic intervention,
when needed, was applied in accordance with UK National
Guidelines.38 The degree of iron overload was evaluated
retrospectively by quantitative phlebotomy.
Statistical analysis
The data set had 80% power at the 5% significance level to
unravel a decrease in iron overload prevalence from 50%
among the homozygous relatives of patients to 20% among
the homozygous relatives of blood donors. Measurements of
sFe, TIBC, and TS were expressed as mean (SD). Data that
were not normally distributed, such as age and sFn, were
summarised as median (range). Comparisons between
groups were made using a two sample t test or a Mann-
Whitney U test, as appropriate. Frequency differences
between groups were assessed for statistical significance by
means of a x2 or Fisher’s exact test and the results expressed
as odds ratio (95% confidence intervals (CI)). Logistic
regression was used to assess the association between HFE
genotype, iron phenotype, and the recorded environmental
and physiological parameters. Where appropriate, environ-
mental and medical measurements were combined in a
propensity function for use in the logistic regression analysis.
Model construction was performed using the ‘‘Akaike’’
procedure of the statistical programme R39 which allows
minimisation of the model deviance by stepwise inclusion or
exclusion of variables, beginning with a null model. The
presence of the iron phenotype was defined as TS .50% and
sFn .300 mg/l (sFn .200 mg/l for premenopausal women),
and entered into the procedure as a dependent variable.
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Multiple linear regression analysis was used to predict the
SF-36 physical component score from genetic, demographic,
and environmental covariates. All statistical analyses were
performed using SPSS version 10 and Statistica 5.1 custo-
mised programmes.
Ethics approval
Ethics approval for the study was obtained from Bro Taf,
Gwent, and Iechyd Morgannwg regional ethics committees.
RESULTS
Recruitment of first degree relatives of C282Y
homozygous probands
The iron and health status of C282Y homozygous blood
donors has been described previously.31 Family details were
available for 66 of the 72 originally identified probands. A
total of 56 probands (median age at screening 43 years) were
finally available for inclusion in the study. These told us
about 180 eligible relatives of whom 165 (92%) agreed to take
part (96 siblings, 69 parents).
The iron and health status of most of the 69 C282Y
homozygous patients with haemochromatosis identified in
Bro Taf and Gwent have been described elsewhere.16 For the
60 probands, median age at diagnosis was 51 years for males
and 52 years for females. Median time interval since
diagnosis was 2.7 years (range ,1 to 27 years). In total,
121 (85%) of the 143 identified first degree relatives (95
siblings, 26 parents) were included in the study.
All blood donor siblings took part in the survey (or had
died). However, from the somewhat older families of
patients, 20 siblings did not reply or did not wish to take part.
Demographics
Parents and siblings in the clinical group were significantly
older than their respective counterparts in the screened group
(table 1). The latter were significantly more likely to have a
history of blood donation, although the mean number of
units of blood donated in a lifetime was not significantly
different. Siblings reported consuming more units of alcohol
per week than their parents but the differences were not
statistically significant when analysed within proband
groups.
A total of 277 relatives (97%) provided data on the ancestry
of all four grandparents. All except two families described
themselves as being of Northern European descent and 244
(85%) claimed some ‘‘Celtic’’ descent, defined as Welsh,
Scottish, or Irish. A total of 169 relatives (59%) had at least
75% Celtic ancestry, 44% had four Celtic grandparents, and
35% had four Welsh grandparents.
Causes of death among relatives
The observed number of C282Y homozygous siblings of
probands (n = 50, 26.4%) was close to the number expected
from the population frequency of HFE C282Y. This suggests
that there is no major excess of sibling deaths arising from
haemochromatosis, an assertion that is further corroborated
indirectly by assessment of the causes and circumstances of
death among deceased first degree relatives. Four deaths (all
male) had occurred among the 51 male and 49 female
siblings from the blood donor families, three of which
occurred neonatally or during infancy (stillbirth, ‘‘convul-
sions’’, and pneumonia). The fourth had died at the age of
38 years of carcinoma of the pancreas. Of the 69 male and 77
female siblings of the clinical cases, 22 and nine had died,
Table 1 Demographic characteristics of first degree relatives (n = 286) of C282Y homozygous probands
First degree relatives of C282Y
homozygotes detected by genetic
screening (n = 165)
First degree relatives of C282Y
homozygotes presenting with
clinical haemochromatosis (n = 121)
Parents Siblings Parents Siblings
No of cases 69 96 26 95
Age (y) 66 (44–89) 43 (14–73) 72 (45–88)* 53 (20–82)***
Sex ratio (F:M) 35:34 49:47 16:10 56:39
History of blood donation (%) 21 (30.4) 42 (43.8) 9 (34.6) 24 (25.3)**
Units of blood donated in lifetime, all relatives 5.3 (12.6) 5.2 (8.4) 5.4 (11.3) 3.6 (9.1)
0.0 (0–60) 0.0 (0–30) 0.0 (0–48) 0.0 (0–63)
Units of blood donated in lifetime, blood donors only 17.3 (17.8) 11.4 (9.2) 15.6 (14.8) 13.6 (13.6)
10.0 (1–60) 10.0 (1–30) 12.0 (1–48) 9.5 (1–63)
Units of alcohol consumed per week 8.3 (14.8) 12.5 (17.1) 6.9 (9.8) 11.6 (23.2)
Measurements are given as mean (SD) and median (range).
Note: one unit of alcohol contains 8 g alcohol.
For each variable, comparisons were made separately between the two parent and the two sibling groups, respectively: *p(0.05, **p(0.01, ***p(0.0001.
Table 2 HFE genotype and haematology for 282 first degree relatives of C282Y
homozygous probands
Genotype
(C282Y/H63D)
Parents (%)
(n = 92)
Siblings (%)
(n = 189) Hb (g/dl) MCV (fl) MCH (pg)
22/22 0 38 (20.1) 14.0 (1.00) 90 (5) 30.0 (2.0)
22/+2 0 20 (10.6) 14.2 (1.52) 89 (7) 29.9 (2.6)
22/++ 0 2 (1.1) 13.8 (0.85) 88 (1) 29.7 (0.3)
+2/22 68 (73.9) 65 (34.4) 14.1 (1.42) 91 (5) 30.3 (2.0)
+2/+2 15 (16.3) 14 (7.4) 14.6 (1.50) 93 (6) 31.3 (2.3)*
++/22 9 (9.8) 50 (26.4) 14.3 (1.59) 94 (5)*** 31.5 (1.8)***
Measurements are given as mean (SD).
Hb, haemoglobin; MCV, mean corpuscular volume; MCH, mean cell haemoglobin.
Comparisons of blood parameters were made between individual genotypes and wild-type genotype (22/22).
*p(0.05, ***p(0.001.
Note: data for one parent had to be omitted as DNA analysis revealed non-paternity.
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respectively. There were eight neonatal/infant deaths, four
accidental deaths, eight deaths due to cancer, three from
myocardial infarction, three from respiratory disease, three
from unknown causes, and two from liver disease. Twelve
were aged 60 years or over.
Genotypes and haematology
The observed genotype frequencies for siblings of C282Y
homozygous probands (table 2) did not differ from those
expected from the population frequencies31 of the three most
common HFE variants, namely wild-type, C282Y, and
H63D.40 Mean corpuscular volume (MCV) and mean cell
haemoglobin (MCH) were significantly higher in C282Y
homozygous compared with ‘‘wild-type’’ homozygous rela-
tives (table 2). MCH, but not MCV, was also significantly
higher in compound heterozygotes for C282Y and H63D. No
significant differences were observed for haemoglobin, red
blood cell, count and haematocrit (data not shown) between
individuals grouped according to HFE genotype.
Genotypes and iron status
Compared with relatives lacking mutations (table 3), a
statistically significant increase in TS and sFn was observed
only in C282Y homozygotes. Thirty four (12%) of the first
degree relatives were discovered to have the ‘‘iron pheno-
type’’, defined as both raised TS and sFn. Thirty of these were
C282Y homozygous (11 females, 19 males), one lacked C282Y
and H63D, one was heterozygous for C282Y, and two were
compound heterozygotes. Thus 32% of female homozygotes
and 76% of male homozygotes showed biochemical evidence
of iron overload (Fisher’s exact test for sex difference:
p = 0.001). Serum ferritin was significantly higher for men
than women in all except the group lacking C282Y and H63D
(data not shown). A total of 25 C282Y homozygotes (median
age 50 years) were identified among relatives of screened
cases. Their mean TS was 51% and median sFn was 251 mg/l.
TS above 50% was found in five women (33%) and six men
(60%). Three women (20%) and six men (60%) had the
biochemical iron phenotype (p = 0.03). Among first degree
relatives of clinical cases, we identified 34 C282Y homo-
zygotes (median age 53 years) with a mean TS of 60% and a
median sFn of 427 mg/l. TS above 50% was found in 12
women (63%) and 12 men (80%). Eight women (42%) and
12 men (80%) had the iron phenotype (p = 0.04).
Median age of all 286 relatives combined was 55 years
(range 14–89 years) and varied with genotype (table 3).
Compared with relatives lacking mutations (all of whom were
siblings), C282Y heterozygotes and compound heterozygotes
were significantly older. Moreover, a greater proportion in the
latter two groups were parents. A small increase in sFn values
was noted with increasing age for all genotypes although this
trend reached statistical significance only for the relatives
lacking mutations (coefficient of determination r2 = 0.171,
p = 0.009) and C282Y heterozygotes (r2 = 0.088, p = 0.005).
Relatives lacking mutations were significantly older in the
clinical group (56.6 years) than in the screened group
(38.7 years; p(0.0001). The same was true of C282Y hetero-
zygotes. Despite these age differences, there were no significant
differences in iron status between the two sets of relatives in
these genotype groups. In contrast, median sFn concentrations
in the two C282Y homozygous sibling groups differed sig-
nificantly despite absence of a significant age difference
between the two groups (clinical 427 mg/l; screened 251 mg/l;
p = 0.03).
Iron deficiency
Iron deficiency, defined as sFn ,15 mg/l, was observed in 18
women (age range 34–78 years) and two men (46 and
54 years). For further analysis see appendix.
Quantitative phlebotomy
To date, 26 of 59 C282Y homozygous relatives have completed
a venesection programme, 24 have been assessed as currently
not requiring venesection, and assessment is ongoing in six.
Two homozygotes have defaulted on their follow up
appointments and no further details are available for them.
One C282Y homozygote (a 67 year old male sibling, TS 69%,
sFn 596 mg/l) from the clinical group died during the study
period of an unrelated pneumonia complicating fibrosing
alveolitis.
Among the 26 venesected homozygotes, 12 (five females,
seven males) were from the screened family group and 14
(four females, 10 males) were from the clinical group.
Median amount of iron requiring removal for sFn and TS to
fall to recommended levels was 2.3 g (range 0.4–5.2) for the
screened group members and 3.5 g (range 1–8) for the
relatives of clinical patients (p = 0.09). More iron needed to
be removed from men (3.0 g, range 1–8) than from women
(2.3 g, range 0.4–4), although the difference was also not
statistically significant (p = 0.11). Only 10 homozygotes
required removal of more than 4 g of iron (seven from the
clinical group, three from the screened group).
Risk factors for iron overload
Univariate analysis revealed that C282Y homozygosity was
the greatest risk factor compared with all other genotypes
(odds ratio (OR) 56.6 (95% CI 17.3–206)) (table 4). First
degree homozygous relatives of clinical cases were at greater
Table 3 Iron status and HFE genotype of first degree relatives of C282Y homozygous probands
Genotype
(C282Y/H63D)
Proband
group Age (y)
Sex ratio
(F:M)
sFe
(mmol/l)
TIBC
(mmol/l) TS (%)
sFn
(mg/l)
22/22 S 39 (16–73) 9:13 16 (9) 62 (8) 27 (15) 57 (4–381)
C 57 (39–80) 9:8 12 (7) 59 (8) 21 (12) 79 (26–175)
22/+2 S 50 (35–69)* 6:4 16 (9) 62 (6) 26 (14) 46 (6–1368)
C 46 (38–68)* 5:5 15 (6) 61 (7) 25 (10) 47 (10–396)
22/++ S 41 (39–42) 1:1 13 (5) 57 (5) 25 (11) 40 (22–57)
+2/22 S 57 (17–89)**** 45:43 16 (7) 59 (8) 27 (11) 64 (5–451)
C 65 (35–88) 32:13 15 (9) 59 (6) 26 (15) 67 (6–714)
+2/+2 S 68 (43–82)**** 7:7 21 (8) 58 (8) 36 (13) 138 (6–490)*
C 60 (28–76) 7:8 19 (10)* 59 (6) 34 (18)* 106 (11–723)
++/22 S 50 (14–73) 15:10 24 (11)* 50(5)**** 51 (27)*** 251 (6–2607)**
C 53 (20–86) 19:15 29 (11)**** 50 (8)**** 61 (24)**** 427 (12–4000)****
Proband group: S, screened, C, clinical presentation.
sFe, serum iron concentration; TIBC, total iron binding capacity; TS, transferrin saturation; sFn, serum ferritin concentration.
Measurements are given as mean (SD) and median (range).
Comparisons of iron parameters were made between individual genotypes and wild-type genotype (22/22): *p(0.05, **p(0.01, ***p(0.001,
****p(0.0001.
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risk of iron overload than relatives of blood donors (OR 2.76
(95% CI 1.24–6.23)). Possession of at least one H63D
mutation appeared to be protective (OR 0.25 (95% CI 0.04–
1.14)), probably because the two mutations hardly ever occur
on the same chromosome.41 42 Sex was also identified as a
significant cofactor, with males having a significantly greater
risk for iron overload (OR 2.50 (95% CI 1.12–5.63)). That age
was not identified as a significant risk factor (p.0.5), despite
the observed age dependence of sFn, is explicable by the
latter effect being confined mainly to the non-pathological
sFn range for relatives lacking mutations or heterozygous for
C282Y. From data collected at interview about medical
history, dietary history, and lifestyle, seven potential para-
meters modifying iron accumulation were identified in the
univariate analysis as being either significant (p(0.05) or of
borderline significance (0.05,p(0.10), namely H63D car-
riership, history of liver disease, current blood donorship,
having been previously deferred as a blood donor, fresh fruit
consumption, alcohol consumption, and regular aspirin
intake. For the purpose of estimating iron overload risks,
corrected for lifestyle and health status, associated with
homozygosity for C282Y, sex, and proband group, the seven
parameters listed above were collapsed into a single
propensity score and the outcome used as a single explana-
tory variable in a multivariate logistic regression model
(table 5). The resulting model showed that while homo-
zygosity for C282Y explains 42% of the model deviance, and
sex and the propensity score each explain 6%, proband group
was no longer a significant risk factor for iron overload. No
significant interaction was observed between any factors. In
total, 57% of the initial model deviance could be explained by
the selected variables.
Iron status and ancestral haplotype
The ‘‘ancestral’’ haplotype was defined as D6S265-1, D6S105-
8, D6S1260-4 (37). For the 54 C282Y homozygotes that could
be typed, nine (16.7%) had two copies of the ancestral
haplotype, 30 (55.5%) carried alleles suggesting the presence
of one copy, and 15 (27.8%) lacked marker alleles from the
ancestral haplotype. There were no significant differences in
age, sFn, or TS between the three groups (data not shown).
Morbidity in relatives
Compound heterozygotes (C282Y/H63D) had significantly
higher rates of diabetes, hypertension, and heart disease than
relatives lacking the C282Y mutation (table 6).
No significant differences were detected among C282Y
carriers lacking H63D, both heterozygous and homozygous.
The higher morbidity in compound heterozygotes did not
relate to the degree of iron accumulation (table 3). Instead,
the difference in morbidity may have resulted from a
substantial difference in age as compound heterozygotes
were significantly older than the wild-type relatives (median
63 v 44 years), reflecting the high proportion of parents in
this group.
Among C282Y homozygotes, when 13 morbidity compar-
isons were stratified by the presence or absence of the iron
phenotype, a significant difference was detected only for the
proportions with elevated aspartate aminotransferase (AST)
levels. Of the C282Y homozygotes with iron overload, five
(17%) had raised AST levels compared with none among
those without the iron phenotype. All those with raised levels
had a history of regular alcohol intake. When morbidity
among C282Y homozygotes was stratified by proband group
(screened v clinical), the only significant difference to emerge
was a higher prevalence of hypertension among relatives in
the clinical group (7/34 in the clinical group and 0/25 in the
screened group; p,0.05).
Quality of life survey among relatives
The SF-36 QOL questionnaire was completed in full by 152
relatives (94%) from the screened and 109 (90%) from the
clinical group. No significant score differences were observed
between C282Y homozygotes and those lacking mutations
(fig 1). However, the HDCY compound heterozygotes had
significantly lower scores than relatives lacking mutations.
Table 4 Univariate analysis of potential risk factors for iron overload
Parameter
Iron overload
(yes:no) p Value* OR 95% CI
HFE genotype (homozygous C282Y v other) 30.29 v 4.219 (0.001 56.6 17.3–205.6
Proband group (clinical v screened) 22.99 v 12.49 0.009 2.76 1.24–6.23
Sex (M v F) 22.105 v 12.143 0.017 2.50 1.12–5.63
Fresh fruit per week ( 7 v .7) 29.66 v 4.75 0.024 3.28 1.05–11.42
Units of alcohol per week (.5 v (5) 22.113 v 11.130 0.040 2.30 1.01–5.31
OR, odds ratio; 95% CI, 95% confidence interval.
*Only risk factors with a two tailed Fisher p value (0.05 are listed. All other recorded risk factors were either of
borderline significance, including H63D carriership, liver disease, current blood donorship, previously deferred
blood donorship, and aspirin intake (all 0.05,p(0.10), or not significant, including age, diabetes, thyroid
disease, heart disease, history of bleeding disorder or anaemia, iron/vitamin C consumption, red meat intake,
coffee, tea, other dietary/mineral supplements, smoking, and all female specific factors such as menorrhagia and
pregnancy (all p.0.10).
Table 5 Logistic regression modelling of iron phenotype risk
Coefficient Standard error Deviance explained (%) p Value*
Intercept 25.17 0.89 – –
Homozygous C282Y 4.86 0.79 84.15 (41.7%) (0.001
Sex 21.79 0.61 12.72 (6.3%) 0.003
Propensity score 7.31 2.33 11.38 (5.6%) 0.002
Proband group 0.51 0.57 6.66 (3.3%) 0.189
*p value from a z approximation of the maximum likelihood estimate of each regression coefficient.
All p values are two sided except ().
Use of a one sided test for the proband group was justified by the prior expectation that relatives in the clinical
group should be at a higher risk than relatives in the screened group.
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No significant difference in the QOL profiles was observed
between previously diagnosed C282Y homozygotes and newly
identified C282Y homozygotes and relatives lacking muta-
tions. Furthermore, there were no significant differences
between C282Y homozygotes from the screened group and
the clinical group. C282Y homozygotes with or without the
iron phenotype also showed no significant difference in QOL
scores (data not shown).
Relatives with raised AST levels
Nine relatives had elevated AST levels. Median amount of
alcohol consumed per week by those with raised AST levels
was 16 units (range 1–190) compared with 5 units (0–80) for
those with normal AST levels (p,0.018). Five were C282Y
homozygous of whom two had AST values higher than twice
the upper normal limit (45 IU/l). All five C282Y homozygotes
also had raised iron indices, and in all but one liver function
tests returned to normal following lifestyle advice and
venesection. Details of the remaining subjects are given in
the appendix.
Relatives with a previous history of liver disease and
liver biopsy results for newly identified C282Y
homozygotes
Four relatives had a history of liver disease, of whom three
had a history of heavy alcohol consumption. The two C282Y
homozygotes had clinically evident cirrhosis. For further
details see appendix. As a result of our investigations, a
further three C282Y homozygous cases (two females, one
male) had a liver biopsy. All had raised TS and sFn but
normal AST levels. Histology in all three showed grade 2 iron,
but no fibrosis or cirrhosis. There were another three
homozygotes (all male) in whom the sFn level was above
1500 mg/l. They either did not wish to have a biopsy (one
case) or their clinician did not deem it necessary. None had
obvious clinical evidence of liver disease. Their clinical
examination, synthetic liver function (albumin and pro-
thrombin time), haematology (platelet count), and liver
ultrasound scans were all normal.
DISCUSSION
The potential public health impact of iron overload and the
availability of effective treatment make it essential to assess
more accurately the penetrance of HFE gene mutations. In
order to identify evidence for possible genetic modifiers of the
associated haemochromatosis disease phenotype, we have
examined the relative contribution of genetic, environmental,
and physiological factors to both iron phenotype and
morbidity in two groups of first degree relatives of probands,
genetically predisposed to haemochromatosis.
Studying relatives, rather than index cases, limits ascer-
tainment bias, a drawback of many previous investigations.
Studies of blood donors31 have been criticised18 as they
represent a population preselected to be healthy and
relatively young. In addition, blood donation may modify
the iron phenotype although donation is usually followed by
partial compensation through increased iron absorption.43
Our present study would also be rightly criticised if the
relatives of blood donors had given more blood than those of
clinical cases. This was not, however, the case. A mean of 5.2
Table 6 Morbidity and HFE genotype in first degree relatives (n = 282) of C282Y
homozygous probands
Genotype (C282Y/H63D)
22/22 22/+2 22/++ +2/22 +2/+2 ++/22
No (%) 39 (13.8) 20 (7.1) 2 (0.7) 133 (47.2) 29 (10.3) 59 (20.9)
Sex ratio (F:M) 18:21 11:9 1:1 77:56 14:15 34:25
Age (y) 44 (16–80) 49 (35–69) 41 (39–42) 58 (17–89)** 63 (29–82)** 52 (14–86)
Iron phenotype 1 0 0 1 2 30
Diabetes 0 1 (5.0) 0 10 (7.5) 4 (13.8)* 1 (1.7)
Raised AST 0 1 (5.0) 0 2 (1.5) 1 (3.5) 5 (8.5)
Liver disease 0 0 0 2 (1.5) 0 2 (3.4)
Any arthralgia 23 (59.0) 13 (65.0) 2 (100.0) 83 (62.4) 22 (75.9) 36 (61.0)
Distal arthralgia 14 (35.9) 7 (35.0) 2 (100.0) 38 (28.6) 14 (48.3) 23 (39.0)
Severe arthralgia 5 (12.8) 5 (25.0) 1 (50.0) 23 (17.3) 8 (27.6) 9 (15.3)
Joint investigation (x ray) 15 (38.5) 10 (50.0) 0 43 (32.3) 9 (31.0) 18 (30.5)
Lethargy 14 (35.9) 9 (45.0) 1 (50.0) 41 (30.8) 12 (41.4) 25 (42.3)
Thyroid disease 3 (7.7) 2 (10.0) 0 10 (7.5) 3 (10.3) 8 (13.6)
Hypertension 4 (10.3) 5 (25.0) 0 30 (22.6) 10 (34.5)* 7 (11.9)
Heart disease 1 (2.6) 2 (10.0) 0 18 (13.5) 7 (24.1)** 4 (6.8)
Coeliac disease 1 (2.6) 0 0 0 0 0
Upper abdominal pain 4 (10.3) 0 0 11 (8.3) 1 (3.5) 3 (5.1)
Age is given as median (range).
Aspartate aminotransferase (AST) reference range 5–45 IU/l.
Comparisons of measurements were made between relatives of a given genotype and those lacking the C282Y
mutation (that is, genotypes 22/22, 22/+2 and 22/++) except for age where a comparison was made with
wild type (22/22): *p(0.05, **p(0.01.
60
55
50
45
40
35
30
PF RP BP GH VT SF RE MH PCS MCS
*
*
* * *
*
*
*****
***
––/–– (n=36)
––/+– (n=18)
––/++ (n=2)
+–/–– (n=122)
+–/+– (n=26)
++/–– (n=56)
Figure 1 HFE genotype and quality of life (QOL) profile of first degree
relatives of C282Y homozygous probands. Numbers relate to those who
completed the QOL survey (261 of 282 genotyped, 92.6%). Norm
based scoring: higher scores represent better health. For the US
population, mean = 50, standard deviation = 10. PF, physical
functioning; RP, role physical; BP, bodily pain; GH, general health; VT,
vitality; SF, social functioning; RE, role emotional; MH, mental health;
PCS, physical component summary; MCS, mental component summary.
Significance of difference from wild type (22/22):*p,0.05,
**p,0.01, ***p = 0.001.
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and 3.6 units was donated in adult life by the screened and
clinical siblings, respectively. In the UK, 6% of the general
population are current blood donors (www.blooddonor.org.
uk), as were 9.7% of the screened and 5.0% of the clinical
group. Although a univariate analysis of our data suggested a
protective effect against iron overload of blood donation, this
did not reach statistical significance (p = 0.087).
Using genetic, environmental, and physiological factors
recorded in the relatives of genetically predisposed probands,
we have shown that by far the highest risk for iron overload
is associated with C282Y homozygosity. Of the 34 relatives
with both raised TS and sFn, 30 were C282Y homozygous.
Two male compound heterozygotes (7%) showed biochemical
evidence of iron overload confirming the much lower
biochemical penetrance of this genotype31 44–47 in comparison
with C282Y homozygosity. Only two lifestyle parameters
were found to be significant risk factors for the iron
phenotype—namely, high alcohol and low fresh fruit con-
sumption. While the effect of alcohol on indicators of iron
status appears straightforward, the protective effect of high
fruit consumption is more difficult to explain. People who eat
more fruit may also eat more vegetables and less red meat,
but further examination of the data did not confirm this
supposition.
The only HFE genotype associated with significantly higher
morbidity was compound heterozygosity (C282Y/H63D).
Diabetes, hypertension, and heart disease increase in
frequency with age, and compound heterozygotes, being
mostly parents, were indeed the oldest group. That age was
the major determinant of morbidity for all relatives was also
confirmed by a stepwise multiple regression analysis to
predict the SF-36 physical component score from demo-
graphic, genetic, and environmental covariates. In addition to
the observed effect of compound heterozygosity, only age and
(not surprisingly) aspirin intake were highly predictive
(p(0.0001).
Only one difference in morbidity was observed when the
C282Y homozygous relatives were stratified by the presence
or absence of the iron phenotype. Five homozygotes with the
iron phenotype also had raised AST activity, but none of the
others had (p(0.05). This limited difference in morbidity
supports a study from Ireland where the frequency of fatigue,
arthropathy and impotence in C282Y homozygous relatives
was not found to be related to iron overload.48 When
morbidity was compared in our study between C282Y
homozygotes from the screened and clinical group, only the
frequency of hypertension was found to differ significantly.
Neither stratification revealed a significant age difference.
Cirrhosis of the liver and hepatoma represent significant,
albeit less common, complications associated with homo-
zygosity for HFE C282Y.49 50 Only two of 59 C282Y homo-
zygotes were found to have cirrhosis, and although we could
not confidently exclude significant fibrosis in a further three
homozygotes, none of the latter had clinical evidence of
cirrhosis. The prevalence of cirrhosis is therefore low, as
observed in the largest screening study of a general
population to date14 and in Irish C282Y homozygotes
identified through family screening.48 The two C282Y homo-
zygotes with cirrhosis both had a longstanding history of
excessive alcohol intake, consistent with an earlier report of a
substantially higher risk of cirrhosis among HH patients who
drink alcohol excessively.26
Our family based observations are consistent with large
scale surveys of primary care patients15 47 where the incidence
of arthritis, diabetes, and heart disease was no higher than in
subjects lacking C282Y or H63D. However, in both surveys,
there was an increased frequency of self reported liver disease
in C282Y homozygotes. Previous observational studies have
also revealed that patients with diabetes, heart disease, and
arthritis do not have significantly increased frequencies of
homozygosity or heterozygosity for C282Y.51 Furthermore, a
study among subjects recruited prospectively from general
practices in Oxfordshire, in which genetic testing was
prompted by symptoms commonly associated with HH, failed
to identify a single case with an iron loading susceptibility
genotype.52
Our finding that C282Y homozygosity has a poor positive
predictive value for morbidity would seem to weaken further
the case for HH population screening based on HFE
genotyping. As was advocated by some before the discovery
of the HFE gene,53 as well as others more recently,54 screening
based on biochemical testing of iron indices offers the benefit
of detecting only those who are already accumulating iron, as
well as avoiding the problem of identifying large numbers of
people with C282Y homozygosity who may be at low risk of
developing clinical complications from iron overload.
Screening healthy subjects is desirable as inflammation and
infection increase ferritin concentration and decrease trans-
ferrin saturation.55 Cases with iron overload detected in this
way and found not to be homozygous for C282Y or
compound heterozygous may then be tested for mutations
in genes other than HFE, including HAMP and HJV.56
The main aim of the present study was to compare the
relatives of index cases detected by a genetic screening
programme with relatives of clinical cases. We hypothesised
that biochemical expression of the iron phenotype would be
higher in relatives of clinical cases and speculated that the
presence of additional familial modifiers (most likely genetic)
would explain any differences in expression found. Indeed,
biochemical expression was found in 40% of C282Y homo-
zygous relatives from the screening group and in 59% from
the clinical group. The difference was statistically significant
on univariate analysis. In a multivariate logistic regression
analysis, however, only C282Y homozygosity, sex, and a
collapsed propensity score remained important, but not the
proband group. Its univariate effect may therefore be
explicable mainly through confounding by other factors,
although a trend towards a higher risk in relatives of clinical
than screened probands remained discernible.
As only 57% of the variability in iron phenotype was
explicable by the genetic, environmental, and physiological
factors considered here, there must be other yet unidentified
influential factors. These are however unlikely to be of great
clinical importance as we have shown that significant
morbidity is rare in both groups of relatives. Results of the
microsatellite analysis to identify the haemochromatosis
‘‘ancestral’’ haplotype also suggest that modifier genes close
to the HFE gene do not play an important role in altering
biochemical expression in these families, confirming a recent
report by Barton and colleagues.57
The clinical and biochemical observations among a cohort
of C282Y homozygotes ascertained through family history
revealed that HFE C282Y homozygosity has a high pene-
trance in terms of iron accumulation but has poor predictive
value for morbidity. These observations further weaken the
cases for HH population screening based primarily on HFE
genotyping.
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APPENDIX
IRON DEFICIENCY
Iron deficiency, defined as sFn ,15 mg/l, was observed in 18
women (age range 34–78 years) and two men (46 and
54 years). This sex difference was statistically significant
(Fisher’s exact test, p = 0.008). The proportions with iron
deficiency were similar in the two groups of relatives
(screened group 8.7%; clinical group 5.0%). Fifteen of the
18 iron deficient women (83%) were premenopausal. The
proportion of relatives with iron deficiency varied with HFE
genotype, from 5% (n = 3) among C282Y homozygotes to
15% (n = 3) among individuals heterozygous for H63D, but
none of the differences reached statistical significance. One of
the iron deficient women had a recent diagnosis of coeliac
disease, 11 had a history of menorrhagia, and 16 had one or
more children. None was vegetarian, but nine had a history
of blood donation (five were current donors). These women
had donated a mean of 15.8 units of blood during adult life
(two women had donated 30 units). Nine relatives (eight
females, one male) had iron deficiency and anaemia.
RELATIVES WITH RAISED ASPARTATE
AMINOTRANSFERASE (AST) LEVELS
Nine relatives had elevated AST levels. Five were C282Y
homozygous. The remaining subjects included two C282Y
heterozygotes (one male, one female) with normal iron
indices and minor derangement of AST (57/53 IU/l) of no
obvious cause, a 50 year old obese female compound
heterozygote (normal iron indices, AST 152 IU/l), subse-
quently diagnosed with non-alcoholic fatty liver disease, and
a 57 year old male H63D heterozygote (TS 41%; sFn 1368 mg/l;
AST 115 IU/l; MCV 100 fl) with a history of heavy alcohol
consumption. Our investigations also revealed type II diabetes.
After management of his diabetes and a reduced alcohol intake,
AST level returned to normal and his sFn fell to 425 mg/l.
RELATIVES WITH A PREVIOUS HISTORY OF LIVER
DISEASE
Four relatives had a history of liver disease. Two were C282Y
heterozygous and two were C282Y homozygous. One hetero-
zygote was the 60 year old father of a blood donor index case.
He had finished a course of chemotherapy for carcinoma of
the colon with liver metastases prior to interview. The other
C282Y heterozygote was a 53 year old female sibling from the
clinical group with normal iron indices. She had a history of
heavy alcohol consumption and was previously diagnosed
with alcoholic hepatitis (no liver biopsy). Her liver function
tests returned to normal with abstinence and remained
normal at interview. Her brother is currently being treated for
haemochromatosis and another brother died, possibly of liver
cirrhosis, at the age of 31 years. Both C282Y homozygotes are
siblings of clinical cases and were detected through family
screening. One, a 47 year old male with a history of heavy
alcohol consumption, was found at liver biopsy to have grade
4 haemosiderosis with fibrosis and possible early cirrhosis. He
had 5 g of iron removed at venesection and is currently well
on a maintenance venesection programme. The other, a
48 year old female, had a clinical diagnosis of chronic liver
disease and a history of postoperative acute hepatic failure
(TS 91%; sFn 4000 mg/l at review). She was a heavy drinker
(.190 units alcohol per week) and had clinical signs of chronic
liver disease. Her liver function tests were abnormal at
presentation (AST 125 IU/l, alkaline phosphatase 273 IU/l).
She was an inconsistent attendee and did not have liver biopsy.
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